VolitionRx announced a 300% revenue increase in Q1 2026, reaching $1 million, driven by progress in their Capture-Seq™ cancer detection platform and Nu.Q® veterinary cancer tests. The company submitted a clinical manuscript for a feline lymphoma test, expecting a $5 million milestone payment, and is engaged in licensing talks with over a dozen global diagnostic firms. Their technology shows over 95% sensitivity for early-stage cancers and is expanding into sepsis detection with a finger-prick test. VolitionRx aims to secure licensing deals to commercialize their multi-billion dollar market opportunities, with routine clinical use in lung cancer expected in France by end of 2026.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
